Keybank National Association OH Has $1.54 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Keybank National Association OH cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 41.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,985 shares of the biotechnology company’s stock after selling 19,707 shares during the period. Keybank National Association OH’s holdings in BioMarin Pharmaceutical were worth $1,538,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BMRN. Principal Financial Group Inc. boosted its position in BioMarin Pharmaceutical by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 455,485 shares of the biotechnology company’s stock worth $32,198,000 after buying an additional 1,549 shares during the period. GF Fund Management CO. LTD. boosted its position in BioMarin Pharmaceutical by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,880 shares of the biotechnology company’s stock worth $345,000 after buying an additional 878 shares during the period. IFM Investors Pty Ltd boosted its position in BioMarin Pharmaceutical by 5.1% during the 1st quarter. IFM Investors Pty Ltd now owns 38,328 shares of the biotechnology company’s stock worth $2,694,000 after buying an additional 1,874 shares during the period. Byrne Financial Freedom LLC boosted its position in BioMarin Pharmaceutical by 4.4% during the 1st quarter. Byrne Financial Freedom LLC now owns 3,852 shares of the biotechnology company’s stock worth $272,000 after buying an additional 161 shares during the period. Finally, OMNI 360 Wealth Inc. acquired a new stake in BioMarin Pharmaceutical during the 1st quarter worth approximately $228,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on BMRN. Barclays cut their target price on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Truist Financial lowered their price target on shares of BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, October 28th. Guggenheim raised their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. UBS Group raised their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Finally, Zacks Research lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Sixteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $90.70.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $53.57 on Monday. The company has a fifty day moving average of $54.78 and a 200-day moving average of $57.06. The firm has a market capitalization of $10.29 billion, a P/E ratio of 20.14, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a twelve month low of $51.00 and a twelve month high of $73.51.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.